基亞生物科技股份有限公司／Medigen Biotech Corp.
基亞生物科技股份有限公司／Medigen Biotech Corp.
  • About
    • Company Overview
    • Our Vision
    • Corporate Structure
    • Corporate Governance
      • Board of Directors
      • Remuneration Committee
      • Organization and Operation of Internal Audit
      • Corporate Governance Status
      • Corporate Regulations
      • Corporate Social Responsibility Status
    • Management
    • Careers
    • Subsidiaries
      • Medigen Vaccine Biologics Corporation
      • TBG Diagnostics Limited
      • Winston Medical & Biotech Group
  • Cell Therapy
    • MAGICELLl–NK (Natural killer cells)
    • MAGICELL®-GDT​(T cells)
    • GTP certificated cell processing facility
    • Cell Therapy Cooperation Agency
    • Cell Therapy Regulation in Taiwan
  • COVID-19
  • Drug Development
    • PI-88 (MUPARFOSTAT)
    • OBP-301 (Telomelysin)​
  • NEWS
    • Material Information
      • 2021
    • Financial Statement
    • Shareholder Services
  • Investors
    • Financial Statements
      • Monthly Revenue Statement
      • Quarterly and Annual Report
    • Shareholder Services
      • Share Price
      • Shareholder Meeting Document
    • Contact Information
    • Stakeholders
  • Language
    • 中文 (繁)
    • English
    • 中文 (简)
  • TBG_COVID19_FDA_CE_20210331
  • 1460X450_1-1
  • Medigen-GDT-TW-V210-sub-1080p.mp4_20201113_112711.5631920763
  • 1232

Cell Therapy Technology

Magicell NK

Magicell GDT

Cell Processing Facility in Taiwan

Cell Therapy Cooperation Agency
14F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C)‧Copyright© 2021 Medigen Biotechnology Corp. All rights reserved.